Last updated: September 2026
Psychedelic research is happening across the world, with researchers asking questions that extend beyond whether psychedelics may help with specific mental health conditions.
Recent studies have examined changes in brain activity, treatment-resistant depression, movement and cognition, end-of-life distress, and psychedelic use outside clinical trials.
This article highlights several international studies published in 2026 and what their findings can, and cannot, tell us.
What Researchers Are Studying
Psychedelic research can look very different depending on the study.
Some researchers conduct controlled clinical trials, where participants receive a psychedelic under carefully monitored conditions. Others use brain imaging to examine what happens during psychedelic experiences. Population studies may instead ask thousands of people about their real-world experiences.
These differences matter. A finding from a small clinical trial cannot automatically be applied to people using psychedelics outside research settings, and an association found in a survey does not prove that a psychedelic caused an outcome.
Research Findings
🇦🇺 Australia: Psilocybin and Movement
Researchers in Melbourne studied whether healthy adults could complete movement and coordination tasks during the acute effects of psilocybin.
Thirteen participants received doses ranging from 5 to 20 mg. Participants were generally able to complete movement tasks at doses up to 15 mg. At 20 mg, researchers observed poorer performance on some tasks that required both movement and cognitive processing.
The study may help inform future research into psychedelic-assisted physical rehabilitation. However, it was a small Phase 1 study in healthy adults. It did not test whether psilocybin improves rehabilitation or treats neurological or movement conditions.
🌍 Multinational Research: Psychedelics and Brain Networks
Researchers combined 11 functional MRI datasets collected across five countries and three continents. The analysis included more than 500 brain scans from 267 participants involving psilocybin, LSD, mescaline, DMT, and ayahuasca.
Across the datasets, psychedelics were associated with changes in communication within and between established brain networks. Some normally distinct networks appeared to become less separated during acute psychedelic effects.
The study provides evidence about how psychedelics may temporarily change large-scale brain organization. It does not establish that these brain changes cause improvements in mental health or other clinical outcomes.
🇬🇧 United Kingdom: Psilocybin and Treatment-Resistant Depression
A randomized controlled trial in England studied psilocybin-assisted therapy for treatment-resistant depression within the National Health Service.
Sixty participants received either 25 mg of psilocybin or placebo with psychological support. Depression scores improved more in the psilocybin group three weeks after treatment, with differences also observed at six weeks.
The findings support continued research, but the study was relatively small and was designed partly to determine whether this type of treatment could be studied within the NHS. Larger confirmatory trials are still needed.
🇩🇪 Germany: A More Complicated Depression Finding
The German EPISODE trial included 144 adults with treatment-resistant major depression who received 25 mg psilocybin, 5 mg psilocybin, or a comparator alongside psychological support.
The trial did not meet its primary outcome at six weeks. However, some secondary measures of depression severity showed greater improvement after 25 mg of psilocybin.
This difference is important. Positive secondary findings do not erase a negative primary outcome. The study adds to the evidence being gathered around psilocybin and depression while also showing why larger trials and predefined outcome measures matter.
🇨🇦 Canada: Psilocybin Microdosing in Palliative Care
Canadian researchers studied repeated low doses of psilocybin among people with advanced, incurable illnesses who were experiencing psychological or existential distress.
Twenty people enrolled, 17 began treatment, and 13 completed the intervention. Among those who completed it, researchers reported improvements in measures including depression, anxiety, and demoralization. No serious adverse events were reported.
The study was open-label and did not include a placebo group. Because of its small size and design, researchers cannot determine whether psilocybin caused the improvements. The findings provide early information that can help guide larger controlled studies.
🌎 Cross-National Research: Psychedelic Use Outside Clinical Trials
Researchers also examined psychedelic use across Canada, the United States, Australia, and New Zealand using data from the International Cannabis Policy Study.
Participants reported their experiences with psilocybin, LSD, MDMA, and ketamine, including reasons for use and adverse health effects. Among people reporting past-year psychedelic use, more than one-third reported an adverse health effect.
This does not mean that one-third of individual psychedelic experiences resulted in an adverse event. The study relied on self-reported information and grouped several substances with different effects and risks.
The findings help show why results from controlled clinical trials should not automatically be applied to psychedelic use in everyday settings.
Risks and Limitations
Psychedelic research varies widely in study size, design, dose, setting, psychological support, and the populations being studied.
Some studies included here involved fewer than 20 participants, while others combined information from hundreds or thousands of people. Some used controlled conditions, while others relied on self-reported experiences.
Psychedelics can also produce difficult psychological experiences and physical effects. Risks may vary by substance, dose, health history, medications, setting, and other factors.
Early findings should therefore be viewed as part of an evolving body of research rather than proof that a psychedelic is safe or effective for a particular condition.
Why This Research Matters
Looking internationally gives researchers a broader picture of psychedelic science.
Different countries have different healthcare systems, research regulations, cultural contexts, and approaches to psychedelic treatment. Comparing findings across settings may help researchers identify which results appear repeatedly and which may depend on a particular population, substance, or study design.
It also shows how broad psychedelic research has become. Researchers are studying mental health alongside neuroscience, rehabilitation, palliative care, public health, and real-world patterns of use.
Bottom Line
International psychedelic research in 2026 is examining much more than whether a particular substance “works.”
Researchers are asking how psychedelics affect the brain and body, how they might be studied within healthcare systems, what happens in different clinical populations, and how real-world use compares with controlled research.
The findings remain mixed and developing. Some studies report promising results, while others highlight uncertainty, limitations, or outcomes that are more complicated than a headline might suggest.
This article will be updated as additional international research becomes available.